Neuropace, Inc. — Form 10-Q Summary
Business Context and Reporting Period
NeuroPace is a commercial-stage medical device company focused on the RNS System, a brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The unaudited filing covers the three and six months ended June 30, 2022, with comparisons to the corresponding 2021 periods.
Revenue is generated in the United States from sales to hospitals and comprehensive epilepsy centers. More than 4,000 patients had received the RNS System as of June 30, 2022.
Financial Highlights
| Metric | Q2 2022 | Q2 2021 | Six Months 2022 | Six Months 2021 |
|---|---|---|---|---|
| Revenue | $10.2 million | $12.6 million | $21.6 million | $23.8 million |
| Gross profit | $7.5 million | $9.4 million | $15.7 million | $17.9 million |
| Gross margin | 73.2% | 74.1% | 72.9% | 74.9% |
| Loss from operations | $(11.0) million | $(4.6) million | $(20.7) million | $(8.5) million |
| Net loss | $(12.7) million | $(8.5) million | $(24.2) million | $(17.3) million |
| Net loss per share | $(0.52) | $(0.48) | $(0.99) | $(1.93) |
| Cash used in operating activities | Not separately provided | Not separately provided | $(22.1) million | $(12.0) million |
As of June 30, 2022, cash and cash equivalents were $5.7 million, short-term investments were $86.7 million, and total cash, cash equivalents and short-term investments were $92.4 million, compared with $115.6 million at December 31, 2021. Total assets were $118.5 million and stockholders’ equity was $52.9 million.
Outstanding term debt was $51.0 million, net of debt discount and issuance costs, compared with $49.8 million at December 31, 2021. The secured term loan bears interest at 12.5%, with a 10% backend repayment fee; principal is scheduled to be repaid in a lump sum on September 30, 2025. The company elected the payment-in-kind interest option for Q2 2022, increasing principal by approximately $0.6 million.
Material Changes Versus the Prior Comparable Period
- Q2 revenue declined 19% and six-month revenue declined 10%, primarily because fewer units were sold for initial implant and replacement procedures.
- Replacement procedures represented approximately 21% of Q2 revenue and 22% of six-month revenue, down from approximately 27% in each comparable 2021 period.
- Gross margin declined to 73.2% in Q2 and 72.9% for the six months, primarily because of higher indirect labor costs.
- Research and development expense increased 28% in Q2 and 32% for the six months, reflecting additional personnel, product development, and clinical-study costs.
- Selling, general and administrative expense increased 34% in Q2 and 42% for the six months, driven by additional personnel and stock-based compensation, public-company costs, and higher sales, field-support, and marketing spending.
- Operating losses and net losses expanded materially despite lower interest expense and the absence of the large preferred-stock warrant fair-value expense recognized in 2021.
- Operating cash burn increased to $22.1 million for the first six months, compared with $12.0 million in the prior-year period. Investing cash inflow of $7.9 million primarily reflected sales of short-term investments.
- Stock-based compensation increased to $4.1 million for the first six months from $1.3 million, with $25.6 million of additional unrecognized expense related to unvested options and restricted stock units as of June 30, 2022.
Outlook, Commentary, Risks, and Unusual Items
Management expects continued net losses and negative cash flows for the next several years while it invests in sales and marketing, clinical studies, product development, regulatory activities, and public-company infrastructure. The filing does not provide clear numeric revenue or earnings guidance.
COVID-19 continued to reduce elective procedures, epilepsy-monitoring-unit admissions, patient referrals, and hospital capacity during Q2 2022. Hospital staffing shortages, procedure backlogs, seasonality, and future COVID-19 variants could continue to make revenue and procedure volumes volatile.
Management believes existing cash, cash equivalents, and short-term investments will fund planned operations for at least 12 months from issuance of the interim financial statements. However, the term loan requires minimum annual 2022 net revenue of $43.0 million and minimum cash and cash equivalents of $5.0 million. The company was in compliance as of June 30, 2022, but failure to satisfy these covenants could allow the lender to accelerate the debt and create a need for additional financing.
The company continues to pursue expanded indications for adolescents and generalized drug-resistant epilepsy. The RNS System remains approved for adults with drug-resistant focal epilepsy in the United States. Key risks include regulatory approval, reimbursement, market adoption, competition from surgery and other neuromodulation devices, dependence on single-source suppliers, product liability, clinical-study execution, intellectual property, cybersecurity, and the need for additional capital.
In August 2022, after the reporting date, NeuroPace entered into an exclusive U.S. distribution agreement with DIXI Medical for stereo-electroencephalography electrodes. The agreement requires payments of $2.0 million in Q4 2022 and $1.25 million in each of Q4 2023 and Q4 2024, totaling $4.5 million. Management also expects approximately $1.0 million of incremental Q4 2022 launch expenses.
The company disclosed a CFIUS inquiry concerning a matter that may fall within CFIUS jurisdiction and stated that it is cooperating. A stockholder lawsuit concerning prior reverse stock splits was settled confidentially on August 8, 2022 and dismissed with prejudice on August 9, 2022; the company recorded an immaterial estimated liability as of June 30, 2022.
Management concluded that disclosure controls were effective as of June 30, 2022. A previously reported material weakness relating to segregation of duties over account reconciliations and manual journal entries was remediated as of March 31, 2022.
Investor Verification Checklist
- Verify whether procedure volumes and the patient referral pipeline recover from COVID-19-related disruptions.
- Track compliance with the $43.0 million 2022 revenue covenant and $5.0 million minimum cash covenant under the term loan.
- Assess cash burn relative to the $92.4 million of cash, cash equivalents, and short-term investments and the potential timing of additional financing.
- Evaluate whether expanded FDA indications and related clinical studies progress on schedule.
- Monitor gross-margin trends, replacement-procedure mix, and the effect of the longer device battery life on replacement revenue.
- Assess the commercial and financial contribution of the DIXI distribution agreement, including the $4.5 million contractual payments.
- Review exposure to single-source suppliers, reimbursement changes, product liability, regulatory matters, CFIUS developments, and cybersecurity risks.